INTRODUCTION
The World Health Organization has declared hepatitis C a global health problem, with approximately 3% of the world's population (roughly 170-200 million people) infected with HCV. In the US, approximately 3 million people are chronically infected, many of whom are still undiagnosed. In Egypt the situation is quite worse. In Egypt, hepatitis C is highly endemic, in 2015, a demographic health survey (DHS) was carried out in Egypt revealing HCV anti-body prevalence nationwide of 6.7 % and HCV RNA of 4.4% in age group (1- 
59). [2]
The goal of antiviral therapy is to cure hepatitis C via a sustained elimination of the virus. Importantly, long-term benefits of sustained virological response (SVR) are the reduction of HCV-related hepatocellular carcinoma and overall mortality. Treatment with interferon is associated with troublesome side effects, including influenza-like symptoms, depression, fatigue, and cytopenias, and requires weekly subcutaneous injections. A substantial proportion of patients with HCV infection are either unable or unwilling to receive an interferon based regimen.
[10]
A pilot study evaluated the INF-free combination of SOF+RBV for 12 weeks in HCV-G4 patients of Egyptian ancestry showing 79% SVR12 in Naïve and 59%in experienced patients. [11] This study aims to evaluate the efficacy of Sofosbuvir plus Ribavirin with or without pegylated interferon in management of Egyptian chronic hepatitis C patients. In Group I; Viral load or previous treatment experience didn't has any significant relation with treatment response. But Males were more likely to respond than female significantly. In addition to the age which show significant relationship to response. In Group 2; Viral load, age or previous treatment experience didn't has any significant relation with treatment response. But Males were more likely to respond than female significantly. as it was 90% but in our study it was only 72.3% and it could be due to many reasons ;the large number in our study (1000 patients in comparison to 51 patients in Esmat's trial).In our study we selected the patients with fibrosis stage (F3, F4) only (according to NCCVH protocol) in comparison to Esmat's trial that 23% of subjects were cirrhotics .Our study included 73.5% naïve patients and 26.5% treatment experienced patients, in comparison to Esmat's trial included 14% naïve patients and 63% treatment experienced.
PATIENTS AND METHODS

Conclusion: Addition of Direct Acting
Antivirals (DAAs), like sofosbovir, to the treatment with interferon and ribavirin improved the duration of the treatment and the sustained virological response (SVR). Treating of cirrhotic by PEGINF+SOF+RBV or SOF+RBV leads to increase success rates. Validation of SVR once will be a golden rule.
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